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Abstract
The large extracellular loop of the Schistosoma mansoni tetraspanin, Sm-TSP-2, when fused to a thioredoxin partner and
formulated with Freund’s adjuvants, has been shown to be an efficacious vaccine against murine schistosomiasis. Moreover,
Sm-TSP-2 is uniquely recognised by IgG1 and IgG3 from putatively resistant individuals resident in S. mansoni endemic areas
in Brazil. In the present study, we expressed Sm-TSP-2 at high yield and in soluble form in E. coli without the need for a
solubility enhancing fusion partner. We also expressed in E. coli a chimera called Sm-TSP-2/5B, which consisted of Sm-TSP-2
fused to the immunogenic 5B region of the hookworm aspartic protease and vaccine antigen, Na-APR-1. Sm-TSP-2
formulated with alum/CpG showed significant reductions in adult worm and liver egg burdens in two separate murine
schistosomiasis challenge studies. Sm-TSP-2/5B afforded significantly greater protection than Sm-TSP-2 alone when both
antigens were formulated with alum/CpG. The enhanced protection obtained with the chimeric fusion protein was
associated with increased production of anti-Sm-TSP-2 antibodies and IL-4, IL-10 and IFN-c from spleen cells of vaccinated
animals. Sera from 666 individuals from Brazil who were infected with S. mansoni were screened for potentially deleterious
IgE responses to Sm-TSP-2. Anti-Sm-TSP-2 IgE to this protein was not detected (also shown previously for Na-APR-1),
suggesting that the chimeric antigen Sm-TSP-2/5B could be used to safely and effectively vaccinate people in areas where
schistosomes and hookworms are endemic.
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Introduction
Schistosomiasis ranks among the most important infectious
diseases in tropical regions, resulting in a loss of between 4.5 and
92 million Disability-Adjusted Life Years (DALYs) annually and
almost 300,000 deaths in sub-Saharan Africa alone [1,2,3].
High rates of post-treatment reinfection [1], the inability of
periodic chemotherapy to interrupt transmission [4], the
exclusive reliance on praziquantel as the only chemotherapeutic
option [5,6] and the unsustainability of mass drug administra-
tion [7] has led to the development of new anti-schistosomiasis
control measures, inlcuding vaccines, to complement existing
initiatives [5,8,9].
Molecules lodged in the apical membrane of the schistosome
tegument represent vulnerable targets for immunological
attack by host antibodies due to their intimate association
with the host immune system. One such family of molecules –
predicted by proteomic analyses of the schistosome tegument
to be accessible to host immunoglobulin [10] – is the
tetraspanin integral membrane proteins. Tetraspanins contain
four transmembrane domains and two extracellular loops that
are predicted to interact with exogenous ligands [11,12].
Indeed, the second extracellular loop of one of these
schistosome tetraspanins, Sm-TSP-2, has proven to be an
effective anti-schistosomiasis vaccine, eliciting 57–64% pro-
tection in mice vaccinated with the antigen followed by
challenge with S. mansoni cercariae [12]. Other schistosome
tetraspanins are protective in mouse models of schistosomiasis
[10], including Sm23 [13,14] and Sj-TSP-2, an S. japonicum
orthologue of Sm-TSP-2 [15]. Moreover, Sm-TSP-2 was
strongly recognised by IgG1 and IgG3 from putatively
resistant but not from chronically infected individuals [12],
further highlighting the promise of this antigen as a subunit
vaccine against human schistosomiasis.
The tegument of adult and schistosomula of S. mansoni is
thinner and distinctly more vacuolated compared to controls
after in vitro treatment with Sm-tsp-2 double-stranded RNA
(dsRNA) [16]. Moreover, injection of mice with schistosomula
pre-treated with Sm-tsp-2 dsRNA resulted in the recovery of
83% fewer parasites from the mesenteries compared to
controls [16], highlighting the importance of Sm-TSP-2 in
proper tegument development and worm survival, and
providing a potential mechanism by which the vaccine exerts
its protective effect.
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In an earlier study, we reported the production of a chimeric
form of Sm-TSP-2, consisting of Sm-TSP-2 fused to the
immunodominant and neutralizing 5B region of the hookworm
aspartic protease Na-APR-1, termed Sm-TSP-2/5B [17]. Hook-
worm infection and schistosomiasis caused by S. mansoni are co-
endemic in much of sub-Saharan Africa and Brazil, and there is
potential interest in developing a vaccine that targets both of these
high prevalence and high disease burden helminths [18]. Na-APR-
1/5B is a 40 amino acid fragment of the protease that contains an
immunodominant alpha helix, A291Y, which is the target epitope
recognized by polyclonal and monoclonal antibodies that are
capable of neutralizing the catalytic activity of Na-APR-1 [17]. Na-
APR-1/5B could not be produced in soluble form, but when fused
to Sm-TSP-2, it was produced in soluble form by E. coli and
induced antibodies upon vaccination that neutralized the enzy-
matic activity of Na-APR-1; the chimera is currently under
investigation as a hookworm vaccine. Using a mouse model of
schistosomiasis, we explored the efficacy of the Sm-TSP-2/5B
chimera in comparison to Sm-TSP-2 alone when both antigens are
formulated with alum/CpG. Given the recent safety concerns of
helminth vaccines that elicit an IgE response in individuals
residing in an endemic area [19], we also assessed the recognition
of Sm-TSP-2/5B by IgE from individuals chronically infected with
S. mansoni, a crucial step in determining whether or not this antigen
could be used to safely and effectively vaccinate people in areas
endemic for both hookworms and schistosomes.
Methods
Ethics Statement
All work involving experimental procedures with laboratory
animals was approved by the animal ethics committee of James
Cook University according to the regulations of the Australian
Code of Practice for the Care and Use of Animals for Scientific
Purposes, 7th edition (reference EA16). All work involving human
subjects research was approved by the Human Research Ethics
Committees or Institute Review Boards of Instituto Rene´ Rachou-
FIOCRUZ, the Brazilian National Committee for Ethics in
Research (CONEP), George Washington University Medical
Center, and the London School of Hygiene and Tropical
Medicine. Informed written consent was obtained from all adults
or the parents and guardians of all children involved in the study.
Antigen production
Oligonucleotide primers incorporating NdeI and XhoI restriction
sites (forward primer: GCGCATATGGAAAAGCCCAAGGT-
CAAAAAACAC; reverse primer GCGCTCGAGGTGCGCTT-
TGCTTAGATCGCTGAC) and pfu turbo DNA polymerase
(Stratagene) were used to amplify the extracellular loop 2 region
(Glu-107 – His-184) of the S. mansoni tetraspanin Sm-TSP-2 from
the pBAD/TOPO/Sm-TSP-2 plasmid [12] in our laboratory. The
amplicon was then cloned into the NdeI and XhoI sites of the
pET41a expression vector (Novagen), removing the GST fusion
tag to allow for native N-terminal expression of the protein, but
retaining the vector’s C-terminal 66his tag to facilitate purification
by Immobilised Metal Affinity Chromatography (IMAC). The
ensuing plasmid was then transformed into chemically competent
E. coli BL21-AI cells (Invitrogen). Sm-TSP-2 was expressed using
the auto-induction method and media formulations established by
Studier [20]. Briefly, 10 ml of minimal media supplemented with
50 mg/ml kanamycin (MDGkan) was inoculated with a single,
recombinant BL21-AI colony and grown overnight at 37uC with
shaking (225 rpm). The entire overnight culture was then used to
seed 1.0 L of defined media supplemented with 50 mg/ml
kanamycin (ZYM-5052-Akan), which was incubated for 24 hours
at 37uC with shaking (225 rpm). Bacteria were pelleted, lysed and
the resultant homogenate purified by (IMAC) as described
previously [17]. Purified Sm-TSP-2 was buffer-exchanged in a
dialysis bag (Pierce) with a cut-off size of 3 kDa against two
changes of 50 mM sodium phosphate, pH 6.5, 10 mM NaCl
(CEX buffer) (2.0 L each) at 4uC for at least 2 hours and then
further purified by passing through a pre-packed 5.0 ml Hi-Trap
SP-FF column (GE Healthcare) (equilibrated with 10 column
volumes of CEX buffer) at a flow rate of 1.0 ml/min using an
AKTA Prime UPC FPLC unit (GE Healthcare). Bound protein
was purified by washing with resuspension buffers containing a
rising concentration (10–500 mM) of NaCl and eluting in 5
column volumes of elution buffer (50 mM sodium phosphate,
pH 6.5, 1.0 M NaCl). Sm-TSP-2 was desalted in a dialysis bag
(Pierce) with a cut-off size of 3 kDa against two changes of PBS
(2.0 L each) at 4uC for at least 2 hours and the final protein
concentration was adjusted to 1.0 mg/ml using an Amicon Ultra-
15 centrifugal concentration device (Millipore).
Sm-TSP-2/5B was produced in E. coli and purified as previously
described [17]. The pMal-4E plasmid encoding Maltose Binding
Protein (MBP) was kindly provided by Dr F. Cardoso and MBP
was expressed in E. coli and purified on amylose resin according to
the manufacturer’s instructions (New England Biolabs).
Generation of rabbit antisera
An emulsion containing 100 mg of Sm-TSP-2 or Sm-TSP-2/5B
(1.0 mg/ml) and an equal volume of Freund’s complete adjuvant
was subcutaneously injected into a single New Zealand White
rabbit. The same amount of antigen emulsified in an equal volume
of Freund’s incomplete adjuvant was similarly administered 2 and
4 weeks later. The rabbit was bled 2 weeks later and the serum
collected by centrifugation.
Recognition of parasite-derived Sm-TSP-2 using rabbit
antisera
Freshly perfused adult S. mansoni were fixed in 100% methanol
overnight at 4uC, embedded in Tissue-tek Optimal Cutting
Temperature compound (ProSciTech) and cryostatically sectioned
into 7.0 mm sections. Sections were rehydrated in PBS and
blocked with PBS/0.05% Tween 20 (PBST)/1% Foetal Calf
Serum (FCS) for 1 hour at RT. After washing twice (5 minutes
Author Summary
There are currently no vaccines available to combat
helminth (worm) infections in humans. The most devas-
tating of the diseases caused by human helminths are
schistosomiasis (or bilharzia) and hookworm disease. By
fusing one of the lead schistosomiasis vaccine antigens,
Sm-TSP-2, with a protective fragment from one of the lead
hookworm vaccine antigens, Na-APR-1, we have produced
a chimeric vaccine, termed Sm-TSP-2/5B that might
provide protection against two debilitating and co-
endemic neglected tropical diseases. Sm-TSP-2/5B provid-
ed increased protection compared to Sm-TSP-2 alone
when formulated with human approved adjuvants and
tested in a mouse model of schistosomiasis. Moreover, IgE
against Sm-TSP-2 or Na-APR-1 has not been detected in
the blood of residents from an area in Brazil that is
endemic for schistosomes and hookworms, indicating that
vaccines based on these molecules would be unlikely to
generate allergic reactions in recipients from developing
countries.
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each) with PBST, sections were incubated with either anti-Sm-
TSP2, anti-Sm-TSP2/5B or naive rabbit sera (8.0 ml in 200 ml
PBST/1% BSA) and 5.0 ml methanolic Alexa Fluor 488-
Phalloidin (Invitrogen) for 1 hour at RT and then washed again
(365 minutes each). The sections were then probed with goat anti-
rabbit IgG-Cy3 (Jackson) (1:500 in PBST/1% BSA) for 1 hour at
RT. After a further 3 washes with PBST, slides were air dried
briefly and mounted with cover slips using PBS/50% Vectorshield
mounting medium with DAPI (Vector Industries) to stain nuclei.
These were examined using a Leica IM1000 DMIRB inverted
fluorescence microscope.
Neutralization of hemoglobinolysis by anti-Sm-TSP-2/5B
antibodies
The inhibition of hemoglobin digestion by Na-APR-1 using
anti-Sm-TSP2/5B IgG was performed as described previously
[17]. An equal amount of anti-Sm-TSP-2 IgG was used as a
negative control.
Study population
The study was conducted in Americaninhas, a rural community
in northeast Minas Gerais state, Brazil and has been described in
detail [12]. The study design was a total population survey, with all
individuals in a 10 km2 area eligible for inclusion. All participants
excluded from the study were offered a fecal exam and treated for
all helminth infections, but were not considered part of the data set
for analysis. Women who were evidently pregnant, or who tested
positive on a urine pregnancy test received treatment for all
helminth infections after the end of the pregnancy or the
termination of breast-feeding.
Parasitological survey
The parasitological survey and blood draw were performed
during April-July 2004, the results of which can be found in Table 1.
Subjects were asked to provide two fecal samples on two separate
days, which were examined qualitatively by formalin-ether
sedimentation. Helminth-positive samples were then examined by
Kato–Katz fecal thick smear to quantify the intensity of infection, as
eggs per gram of feces (epg). Two slides were counted from each
day’s sample, i.e. 2–4 slides from each individual, as some
individuals only provided one sample. Individuals who were egg-
positive by sedimentation but negative by Kato-Katz were assigned
a count of 3 epg, half the Kato-Katz detection limit. Hookworm was
exclusively N. americanus. Adults or children positive for gastrointes-
tinal nematodes were offered a single 400 mg dose of albendazole
and individuals infected with S. mansoni were treated with
praziquantel. Egg-negative individuals were not treated. Treated
individuals were examined post-treatment to confirm treatment
efficacy, and offered repeat treatment(s) until egg-negative.
Determination of human IgE responses against Sm-TSP-2
Approximately 20 ml of blood was collected from 666
volunteers in siliconized tubes for separation of serum. In brief,
the level of IgE against Sm-TSP-2 was measured by indirect
ELISA using Polysorp 96-well microtiter ELISA plates (NUNC
F96, Fisher Scientific) which were incubated overnight at 4uC with
antigen (1 mg/ml in 0.15 M PBS, pH 7.2). After washing with
PBST, the plates were blocked for 2 hours at RT with 250 ml of
PBST/3% BSA. One hundred microliters of sera (1:25 in PBST/
3% BSA) were added to the wells and incubated overnight at 4uC,
then the plates were washed with PBST and 100 ml of mouse
biotin-conjugated monoclonal anti-human IgE FC (Human
Reagent Laboratory, Baltimore, MD) (1:200 in PBST/3% BSA)
was added to the plates. Plates were incubated for 2 hours at RT
and then washed with PBST. Plates were developed by adding o-
Phenylenediamine dihydrochloride in 0.05 M phosphate-citrate
buffer (pH 5.0) plus 30% hydrogen peroxide H2O2 for 30 minutes
at RT in the dark. Fifty microliters of 2N H2SO4 was added to
stop the colorimetric reaction, which was read at a wavelength of
490 nm on a SpectraMax 340 PC (Molecular Devices) microplate
reader. SOFTmax Pro for Windows was used for the analysis and
storage of data.
Mouse immunisation and parasite challenge
Approval for the work described in this study was obtained from
the James Cook University Animal Ethics Committee. Groups of
ten female C57BL/6 mice were immunised with Sm-TSP-2, Sm-
TSP-2/5B, or the control protein MBP. Each antigen (25 mg per
dose) was formulated with an equal volume (25 ml) of a 13 mg/ml
colloidal suspension of aluminium hydroxide gel (alum) (Sigma)
and 5 mg of CpG oligodinucleotide 1826 (CpG) (Invivogen) and
injected intraperitoneally on days 0, 14 and 28. Mice were
challenged on day 42 with 120 S. mansoni cercariae by abdominal
penetration [21]. Trials were conducted twice on different dates
and with different batches of cercariae. Serum samples were
collected at day 22 (pre-immunisation), day 40 (pre-challenge)
and day 91 (necropsy) to assess antibody responses.
Necropsy and estimation of parasite burden
Mouse necropsy and worm and egg burden assessments were
performed as described previously [12]. Reductions in parasite
loads were calculated as percentages of the parasite burden in the
control group. Statistical significance was assigned a threshold of
P=0.05 and values were determined using the student’s t test
function in Graph Pad Prism.
ELISA using pre-challenge and necropsy sera
Individual anti-Sm-TSP-2 titres (total IgG, IgG1 and IgG2a)
were determined for all trial 1 animals just prior to cercarial
challenge and at necropsy using standard ELISA techniques.
Antigen was coated on microtiter plates at 1.0 mg/ml. Sera were
serially diluted (1:1,000 to 1:16,384,000 for total IgG and IgG1
measurements and 1:1,000 to 1:256,000 for IgG2a assessment) and
100 ml was added to each well. After addition of the appropriate
horseradish peroxidase-conjugated goat antibody (Jackson), per-
oxidase activity was detected with tetramethyl benzidine chromo-
genic substrate and measured at 655 nm.
Cytokine ELISAs with restimulated splenocytes
Spleens were taken from all animals from trial 2, and single cell
suspensions prepared by passing through a 70 mm filter (BD
Biosciences). Red blood cell lysis buffer (Sigma) was used to
remove red blood cells. Splenocyte preparations were counted,
and cultured in duplicate at 16106 cells/well in 96-well plates.
Schistosome egg antigen (SEA) and soluble adult worm antigen
preparation (SWAP) were prepared as described respectively
[18,19] and added to the cultures at 10 mg/ml and cultured at
37uC, 5% CO2 for 72 h. Levels of IL-4, IL-10, and IFN-c in cell-




The large extracellular loop of Sm-TSP-2 (Sm-TSP-2) (molecular
weight including 66His tag=10 kDa) was expressed in E. coli using
the auto-induction technique of Studier [20] instead of the more
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conventional method of IPTG induction normally used to drive
protein expression in T7 promoter-based, inducible systems. In
addition to producing an increased biomass despite using identical
seeding conditions and culture volumes, Sm-TSP-2 was produced by
auto-induction and purified by IMAC to a final concentration of
100 mg/L (Fig. 1A), more than twice the yield of Sm-TSP-2 obtained
by IPTG-induction (data not shown). To obtain reasonable yields of
soluble chimeric Sm-TSP-2/5B (molecular weight including 66His
tag=16.1 kDa), the protein required expression in the less reductive
cytoplasmic environment of the slow-growing Rosetta-Gami strain of
E. coli, in addition to being cultured at a sub-optimal growth
temperature of 23uC; as a result, auto-induction of Sm-TSP-2/5B was
not a feasible production method. Nevertheless, when expressed
using IPTG-induction and purified by IMAC, we obtained a yield of
20 mg/L of soluble Sm-TSP-2/5B (Fig. 1B).
Anti-Sm-TSP-2/5B antibodies bind to parasite-derived
Sm-TSP-2 and neutralise the activity of Na-APR-1
The localization of Sm-TSP-2 to the outer tegument of S. mansoni
has previously been documented using an antibody raised to the
thioredoxin fusion protein [12]. The recognition of native Sm-
TSP-2 by anti-Sm-TSP-2/5B antibodies (Fig. 2A) indicated that
parasite-derived Sm-TSP-2 epitopes were faithfully reproduced in
the recombinant protein and were not disrupted by the addition of
the 5B region of Na-APR-1 to the C-terminus of Sm-TSP-2. No
reaction was observed with naive rabbit serum (Fig. 2B). Similarly,
the ability of anti-Sm-TSP-2/5B IgG to bind (and inhibit) Na-APR-
1 hemoglobinase activity demonstrates the preservation of 5B
epitopes within the chimeric protein. No hemoglobinase inhibition
of the enzyme was observed when anti-Sm-TSP-2 IgG was used in
the assay (Fig. 2C).
Table 1. Cohort details of chronically infected individuals used in this study.
Group N Age Necator americanus Schistosoma mansoni
Prev.a Intensity of Infection (EPGb) Prev.a Intensity of Infection (EPGb)
Mean Min Max N (%) Min Max G. Mean 95% CI N (%) Min Max G. Mean 95% CI
Females 309 33.78 1 96 248 (69) 6 62,856 766 (606, 969) 170 (55) 6 4074 93.33 (74, 116)
Males 357 34.30 7 92 252 (82) 6 55,554 692 (559, 857) 155 (43) 6 5952 90.82 (71, 114)
Total 666 33.45 7 92 500 (75) 6 62,856 727 (621, 858) 325 (49) 6 5952 92.12 (78, 108)
a ‘‘Prev.’’ = prevalence of infection.
b ‘‘EPG’’ = eggs per gram of feces as etermined by 2 slides of Kato Katz fecal thick smear for two days.
doi:10.1371/journal.pntd.0001564.t001
Figure 1. Vaccine antigen production. (A) Sm-TSP-2 was ligated to a pET41a vector backbone in-frame with the C-terminal 66His tag, expressed
in E. coli.by autoinduction and purified by IMAC followed by CEX chromatography and desalting into PBS. 1 = uninduced soluble fraction;
2 = autoinduced soluble fraction; 3 = purified protein. (B) Sm-TSP-2/5B was ligated to a pET41a vector backbone in-frame with the C-terminal 66His
tag, expressed in E. coli.by IPTG induction and purified by IMAC and desalting into PBS. 1 = uninduced soluble fraction; 2 = IPTG-induced soluble
fraction; 3 = purified protein.
doi:10.1371/journal.pntd.0001564.g001
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Chronically infected individuals do not produce a
detectable IgE response to Sm-TSP-2
Sera from 666 individuals from Minas Gerais state, Brazil – an
area of high S. mansoni transmission – were assessed for the
presence of an IgE response against Sm-TSP-2. No detectable
levels of anti-Sm-TSP-2 IgE antibodies were observed, despite the
presence of a strong IgE response to SEA in some individuals
(Fig. 3).
Antibody profile following mouse immunization and
parasite challenge
Mice vaccinated with alum/CpG adjuvanted Sm-TSP-2 and
Sm-TSP-2/5B mounted strong Sm-TSP-2-specific IgG respons-
es (Table 2). IgG1 responses dominated and IgG2a responses
were generally weak (not shown). Pre-challenge IgG endpoint
titers (four-fold serial dilutions) ranged from 256,000–
1,024,000 for Sm-TSP-2 vaccinated mice and 256,000–
4,096,000 for Sm-TSP-2/5B vaccinated mice. At necropsy
(post-challenge), titers had waned to 64,000–256,000 for Sm-
TSP-2 vaccinated mice and 64,000–1,024,000 for Sm-TSP-2/
5B vaccinated mice. Mean and median anti-Sm-TSP-2
antibody titers were higher in the group vaccinated with Sm-
TSP-2/5B (means 486,400 vs 1,450,667; medians 256,000 vs
1,024,000), implying that mice vaccinated with the chimera
made a stronger antibody response against the Sm-TSP-2
region of the immunogen, and increased titers were not due to
anti-5B antibodies. No obvious association between antibody
titer and parasite burden was detected. Of the mice vaccinated
with Sm-TSP-2/5B, two mice had no worms, one mouse had
two worms and one mouse had four worms. All four mice had
the lowest liver egg burdens and high antibody titers
($1,024,000). However, two other mice had equally strong
antibody titers but had higher parasite burdens (29 and 34
worms), precluding determination of a robust correlation
between worm burdens and antibody titers.
Vaccination with Sm-TSP-2 and Sm-TSP-2/5B formulated
with alum/CpG protects against parasite challenge
Sm-TSP-2/5B and Sm-TSP-2 formulated with alum/CpG
protected against experimental challenge with S. mansoni.
Vaccinated groups had respective decreases in worm burden of
54–58% (Sm-TSP-2/5B, P,0.01) and 25–27% (Sm-TSP-2,
P,0.05), compared to controls over two independent trials
(Fig. 4A and 4B). A comparative reduction in liver egg burdens
was also observed in these groups – 48–56% (Sm-TSP-2/5B,
P,0.01) and 20–27% (Sm-TSP-2, P,0.05), respectively (Fig. 5A
Figure 2. Anti-Sm-TSP-2/5B antibodies bind to parasite-derived Sm-TSP-2. Immunofluorescence micrograph showing adult male
Schistosoma mansoni sections probed with either (A) rabbit anti-TSP-2/5B serum or (B) naı¨ve rabbit serum followed by goat anti-rabbit IgG-Cy3. Both
sections were also stained with Alexa-Fluor 488 (green staining of actin filaments) and DAPI (blue staining of nuclei). All images are shown at original
magnification663.
doi:10.1371/journal.pntd.0001564.g002
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and 5B). When the data from both trials were combined,
significant decreases in worm and liver egg burdens were seen
between the group vaccinated with Sm-TSP-2/5B and the group
vaccinated with Sm-TSP-2 (P,0.01 and P,0.05, respectively).
Liver egg burdens were not disproportionately reduced compared
with burdens of worms, suggesting no additional effect on
parasite fecundity (Table 2).
Vaccine-induced protection against parasite challenge is
associated with parasite-specific IFN-c production
Splenocytes from vaccinated and challenged animals were
restimulated with SEA and SWAP to assess the cytokine
responses to vaccination and parasite challenge. Levels of IL-
4, IL-10 and IFN-c from splenocytes were elevated in all
infected animals compared to uninfected MBP-vaccinated
animals when restimulated ex vivo with SEA and SWAP
(Figure 6), indicating that infection-related cytokine responses
were produced, although responses to SEA were generally
higher. SEA and SWAP-specific IL-4 responses tended to
increase in Sm-TSP-2/5B-vaccinated animals compared to
control (MBP-vaccinated) infected animals, however this only
reached significance with SWAP restimulation. IL-10 produc-
tion in response to SWAP, but not SEA, was also increased due
to Sm-TSP-2/5B vaccination. IFN-c production in response to
both SEA and SWAP were also highly significantly increased
(P,0.01) in response to Sm-TSP-2/5B vaccination.
Discussion
We have previously demonstrated that the large extracellular
loop of the S. mansoni tegument tetraspanin, Sm-TSP-2, when linked
to a thioredoxin fusion partner and formulated with Freund’s
adjuvants, is an efficacious vaccine antigen, eliciting high levels of
protection in a murine schistosomiasis model of infection [12].
Herein, we show that modified and chimeric forms of the Sm-TSP-2
vaccine antigen are also protective, even when formulated with a
human-approved adjuvant combination, and that a schistosomiasis
vaccine based on Sm-TSP-2 (or Sm-TSP-2/5B) satisfies additional
selection criteria for progression into clinical trials, such as safety
concerns around the potentially deleterious effects of pre-existing
IgE responses in helminth endemic populations [1,19].
There is a paucity of funding - driven by the lack of a
commercially viable market - available for the production of
vaccines against the neglected tropical diseases, and so a vaccine
antigen must be amenable to low-cost manufacture [22]. Despite
attempts at optimisation of production of these two antigens being
preliminary at best, both Sm-TSP-2 and Sm-TSP-2/5B have been
expressed at yields that, at this initial stage, may be indicative of
cost-effective up-scaling and clinical development. Indeed, Sm-
TSP-2 has been recently produced in Pichia pastoris fermentation
cultures in our laboratory at a yield or over 500 mg/L (data not
shown) and efforts are currently underway to express Sm-TSP-2/
5B in a similar fashion.
Figure 3. Chronically infected individuals do not make IgE against Sm-TSP-2. Graph showing human anti-Sm-TSP-2 IgE responses towards
soluble egg antigen (SEA), soluble adult worm antigen (SWAP) and Sm-TSP-2. Antibody responses were determined by indirect ELISA. Dots reflect OD
values of individual people and bars reflect the mean OD values of the groups.
doi:10.1371/journal.pntd.0001564.g003
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We recently suggested that the presence of a pre-existing human
serum IgE response to a helminth vaccine antigen is a down-
selection criterion [1] when considering a molecule for progression
towards clinical trials because of the safety risks involved [19]. No
detectable levels of Sm-TSP-2-specific IgE were found in
individuals chronically infected with S. mansoni, despite very strong
IgE responses to proteins found within SEA. This is also the case
for the hookworm antigen, Na-APR-1 [23], the origin of the 5B
domain in Sm-TSP-2/5B. Despite the absence of a detectable IgE
response, previous studies have shown that humans from
schistosome- and hookworm-endemic areas mount IgG1 responses
to Sm-TSP-2 [12] and Na-APR-1 [23], indicating that both
antigens are recognized by the immune system in a natural
infection. What determines the isotype response (IgG vs IgE)
mounted by an infected individual to a helminth antigen is
multifactorial and an unresolved topic of debate [24]. What is
clear, however, is the potential danger of developing a vaccine
based on an antigen that is the target of a naturally acquired IgE
response in the target population.
Of the two test groups, mice vaccinated with Sm-TSP-2/5B
had the highest level of protection against experimental
schistosomiasis. We initially hypothesized that this increased
protection was due to cross-reactive epitopes within the 5B region
of hookworm Na-APR-1 and its S. mansoni orthologue, Sm-catD
[25]. However, numerous attempts to show binding of anti-Sm-
TSP-2/5B to recombinant Sm-catD and schistosome extracts
using Western blotting and immunoprecipitation coupled to
tandem mass spectrometry (A. Dougall and A. Loukas,
unpublished) were unsuccessful. Anti Sm-TSP-2/5B did, however,
bind strongly to recombinant Na-APR-1 and inhibited the ability
of the enzyme to cleave a synthetic substrate in a previous study
[17] and has likewise been shown to neutralise the hemoglobinase
capacity of Na-APR-1 in this study; indeed, the 5B region of Sm-
TSP-2/5B is highly immunogenic and was the target of a panel of
Table 2. Anti-Sm-TSP-2 IgG titers and parasite burdens of Sm-
TSP-2 and Sm-TSP-2/5B vaccinated groups from trial 1.
Mouse Total IgG titer Total Worms Liver EPGa
Pre-challenge Necropsy
Sm-TSP-2 vaccinated group
1 256,000 64,000 4 14,652
2 256,000 64,000 38 18,722
3 256,000 64,000 30 16,061
4 256,000 64,000 44 18,543
5 1,024,000 256,000 53 16,473
6 256,000 64,000 48 20,430
7 256,000 256,000 25 4,813
8 256,000 64,000 38 13,900
9 1,024,000 256,000 56 16,250
10 1,024,000 64,000 28 11,293
Sm-TSP-2/5B vaccinated group
1 256,000 256,000 32 11,217
2 1,024,000 256,000 0 0
3 256,000 64,000 38 17,296
4 256,000 256,000 51 16,952
5 1,024,000 256,000 34 13,523
6 4,096,000 256,000 29 9,832
7 4,096,000 1,024,000 4 3,681
9 1,024,000 256,000 2 1,700
10 1,024,000 256,000 0 0
a ‘‘EPG’’ = eggs per gram of tissue.
doi:10.1371/journal.pntd.0001564.t002
Figure 4. Worm burdens of vaccinated C57BL/6 mice. All vaccinees were necropsied on day 91, 7 weeks post-challenge. Worms were perfused
from the vasculature with PBS into petri dishes and counted. Reductions and significance (*P,0.05; **P,0.01; *** P,0.001) are represented relative
to the Maltose Binding Protein (MBP) control group. (A) Trial 1 total worms. (B) Trial 2 total worms.
doi:10.1371/journal.pntd.0001564.g004
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IgG1 mAbs raised to recombinant Na-APR-1 [17]. Production of
a chimeric antigen comprising Sm-TSP-2 and the 5B region of
Sm-CatD from S. mansoni instead of Na-APR-1 is currently
underway in our laboratory and may have the additional benefit
of being able to induce an antibody-mediated neutralization of
Sm-TSP-2 in the tegument and Sm-CatD in the gut of the intra-
mammalian stages of S. mansoni. Given the absence of an obvious
cross-reactive schistosome epitope for antibodies to the Na-APR-
1/5B fragment, we therefore sought to confirm whether the
increased protection obtained with Sm-TSP-2/5B compared to
Sm-TSP-2 alone was due to the increased size and therefore
increased immunogenicity of the chimera. When microtiter plates
were coated with Sm-TSP-2 and probed with antisera from mice
immunized with Sm-TSP-2 or Sm-TSP-2/5B, the IgG endpoint
titers were higher on average for the group immunized with Sm-
TSP-2/5B, implying that vaccination with the larger immunogen
resulted in an increased TSP-2-specific antibody titer. We also
noted that individual mice with the highest antibody titers had
the fewest worms, as highlighted in Table 2. Studies are also in
progress to determine whether the chimeric protein generates
similar levels of protection against hookworm infection caused by
Necator americanus.
Figure 5. Liver egg burdens of vaccinated C57BL/6 mice. All vaccinees were necropsied on day 91, 7 weeks post-challenge. Livers were
removed, weighed, digested in 5% KOH overnight at 37uC and the rsulting eggs resuspended in 1 ml formalin. The amount of eggs in multiple 50 ml
aliquots were counted and the number of eggs per gram of tissue (EPG) determined. Reductions and significance (*P,0.05; **P,0.01; ***P,0.001)
are represented relative to the Maltose Binding Protein (MBP) control group. (A) Trial 1 - liver EPG. (B) Trial 2 - liver EPG.
doi:10.1371/journal.pntd.0001564.g005
Figure 6. Protection against parasite challenge is associated with increased IFN-c production. Graphs of ELISA data showing IL-4 (left
axis), IL-10 (right axis) and IFN-c (right axis) production by splenocytes taken from mice at necropsy and restimulated with either (A) schistosome
soluble egg antigen (SEA) or (B) schistosome soluble adult worm antigen (SWAP). All significant differences are compared to the control MBP-
vaccinated, infected group (MBP inf) by ANOVA (**P,0.01, ***P,0.001). Unless otherwise indicated, levels are not significantly different to controls.
doi:10.1371/journal.pntd.0001564.g006
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Restimulation of splenocytes from vaccinated and infected mice
prior to necropsy showed a general increase in both Th2 (IL-4),
regulatory (IL-10) and Th1 (IFN-c) responses to parasite antigens,
which was especially marked in increased IFN-c production by
mice vaccinated with Sm-TSP-2/5B compared to those vaccinated
with the control non-parasite protein MBP. This implies that every
animal was effectively challenged, indicating that the recovery of
very few or no parasites in some mice was not due to an
unsuccessful infection but successful vaccination. These data also
suggest that Th1 cytokines have a role in the protective response
against schistosomiasis, a finding that has been documented in
infection studies with the parasite [26,27] and vaccination
experiments with recombinant vaccine candidate antigens from
the tegument such as Sm29 [28] and Sm14 [29].
A caveat of using human-approved adjuvants to test vaccine
antigens in the early stages of process development is that the full
potential of a candidate antigen may not be realized due to the
increased immunostimulatory properties of adjuvants containing
mycobacteria and other toxic components, such as Freund’s
adjuvants. However, the levels of protection reported herein for
Sm-TSP-2/5B were similar to those reported for Freund’s
formulated thioredoxin-Sm-TSP-2, and well exceed the 40%
benchmark set by the WHO for progression of an antigen into
clinical trials irrespective of the adjuvant used [30].
Sm-TSP-2 immunolocalizes to the surface of schistosomula [16]
and adult worms [12] and has been found in the outer tegument of
mature schistosomes [10] in abundance using proteomic tech-
niques [31]. The ultrastructural morphology of adult worms and
schistosomula treated in vitro with Sm-tsp-2 double-stranded RNA
displayed a distinctly vacuolated and thinner tegument compared
to controls, suggesting that Sm-TSP-2 may play a pivotal role in
tegument development in the early stages of intra-mammalian
development [16]. These insights into Sm-TSP-2 function, along
with the apparent importance of humoral immunity in anti-Sm-
TSP-2 vaccination, lead us to hypothesize that the surface of the
schistosomulum and adult fluke are potential sites of immune
attack where these crucially important membranes are being
opsonized by anti-Sm-TSP-2 antibodies for further attack by
complement, antibody-dependent cellular mechanisms, or both.
We are currently exploring the immunologic mechanisms
responsible for vaccine-induced efficacy using genetically modified
mice.
The Sm-TSP-2-based vaccine antigens reported in this study
appear to exhibit all the early-stage characteristics of a vaccine
targeting developing countries where schistosomiasis is endemic,
based on their ease of production, absence of IgE reactivity,
preferential recognition by resistant humans [12], essential nature
of the protein for parasite survival [16] and vaccine efficacy in
animal models. These features, coupled with the recent finding of
a lack of polymorphism between geographical isolates of Sm-TSP-2
throughout Africa [32] provide a compelling argument for the use
of Sm-TSP-2-based antigens as safe and effective anti-schistosomi-
asis vaccines. These additional studies also open the door to
exploring more than a single helminth target with a single antigen.
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